Since PTPRS was reported to have a tumor suppressor-like role24–26, we postulated that the somatic mutations of PTPRS, if functional, might be inactivating mutations, which could mediate RAS/ERK pathway activation, which is a driver of tumorigenesis3–6. This evidence concerns the gene MAPK1 and neoplasm.